U.S. Specialized REITs Stock News

Cintas (NasdaqGS: CTAS) announced a leadership change, appointing Jim Rozakis as President while Todd Schneider continues as CEO. The company has formally separated the President and CEO roles, signaling a new executive structure for the business. Consider broadening your watchlist with other companies in similar industries through 78 resilient stocks with low risk scores NasdaqGS:CTAS 1-Year Stock Price Chart Cintas operates in the uniform rental and facility services space, an area that...

Collegium Pharmaceutical stock has delivered a 59.8% gain over the past five years, yet the recent share price pullback and a strong set of valuation checks suggest the market may be reassessing how cheap or expensive the current price really is. Over five years, Collegium Pharmaceutical has returned 59.8%, which points to meaningful value creation for longer term holders despite more recent weakness. Future growth in prescriptions and cash flow can support the current market value, while...

A federal court has just put a US$400 million White House ballroom project on ice, and that legal pause shines a harsh spotlight on companies that depend on Washington for big construction and real estate work. When projects stall, revenue visibility can blur fast. This article walks through three stocks exposed to this political drama, all on the wrong side of the news, so you can judge whether their risk profile still fits your portfolio. AECOM (ACM) Overview: AECOM is a Dallas...

Definium Therapeutics (DFTX) drew investor attention after reporting Q2 2026 results that showed a wider net loss and higher loss per share, along with recent Phase III data and financing updates related to its DT120 ODT program. See our latest analysis for Definium Therapeutics. The share price of Definium Therapeutics has reacted strongly to recent Phase III data and financing updates, with a 90 day share price return of 109.25% and a year to date share price return of 238.27%. The 1 year...

Rapport Therapeutics (RAPP) drew fresh investor attention after reporting second quarter 2026 results and outlining progress across its central nervous system pipeline, including new Phase 3 trials for lead candidate RAP-219. See our latest analysis for Rapport Therapeutics. The clinical updates appear to have coincided with a sharp re-rating in investor expectations, with Rapport Therapeutics posting a 1-day share price return of 9.21% and a year to date share price return of 64.89%. The...

Encore Capital Group reported past second-quarter 2026 results showing revenue of US$491.87 million and net income of US$64 million, alongside higher first-half revenue and earnings compared with a year earlier. The company also lifted its full-year 2026 EPS guidance to US$13.00–US$14.00, even after absorbing US$1.00 per share in refinancing costs, and completed a multi-year buyback that has reduced its share count materially. We’ll now examine how this upgraded EPS guidance, despite...

Unity Software stock has rebounded in the short term, yet the valuation picture is mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market based multiples suggest the shares screen as expensive. After a multi year period where the share price declined 67.8% over 5 years, investors now face a gap between what the DCF implies and what traditional valuation checks are signaling. Unity Software shareholders have seen the stock decline 67.8% over 5...

JFrog (FROG) moved into focus after its second quarter 2026 earnings topped market expectations, with cloud and security products playing a central role and management lifting both full year revenue and earnings guidance. See our latest analysis for JFrog. The strong second quarter update comes after a period of mixed share price moves for JFrog, with a 90 day share price return of 17.70% and a year to date share price return of 39.40%. The 1 year total shareholder return of 114.08% points to...

In the past week, RLJ Lodging Trust reported second-quarter 2026 results showing higher sales of US$311.76 million and revenue of US$382.99 million, with net income rising to US$31.04 million and earnings per share from continuing operations edging up to US$0.16. Alongside these results, management raised full-year 2026 net income guidance to a range of US$21.6 million to US$38.6 million, signalling confidence that recent operational momentum can persist. With this upgraded earnings...

Why USA Compression Partners Earnings Caught Investor Attention USA Compression Partners (USAC) drew fresh interest after reporting second quarter 2026 results with higher sales, revenue, and net income compared with a year earlier, along with a reaffirmed focus on disciplined, accretive M&A. See our latest analysis for USA Compression Partners. Against this backdrop, USA Compression Partners’ share price is up 9.63% year to date to US$26.08. Its 1 year total shareholder return of 20.70% and...

Howmet Aerospace stock has delivered very strong returns over the past five years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently suggest the shares trade at a premium rather than at a clear bargain. Howmet Aerospace has returned very close to 8x over the past 5 years, which sets a high bar for any further gains to be supported by fundamentals. Expectations for continued cash flow generation and margin resilience can support the current price,...

JetBlue Airways (JBLU) has been in focus after reporting higher second quarter 2026 revenue along with a wider net loss, updating its operating guidance, setting a 2028 EPS target, and filing a US$121.4 million shelf registration. See our latest analysis for JetBlue Airways. At a share price of US$6.19, JetBlue Airways has seen a 30 day share price return of 8.22% and a 90 day share price return of 21.14%. The 1 year total shareholder return of 43.29% contrasts with weaker 3 and 5 year total...

Trevi Therapeutics (TRVI) has entered a new phase in its development story by kicking off Phase 3 and Phase 2B chronic cough trials while operating with a sizeable cash position that supports ongoing work and potential FDA review. See our latest analysis for Trevi Therapeutics. The latest trial updates and earnings release have come alongside a share price of $18.50, with a 90 day share price return of 27.59% and a year to date share price return of 55.59%. Over the longer term, total...

Oracle (ORCL) is back in focus after CACI International was selected as a technology partner on a nearly US$400 million, 10 year federal HR modernization contract that centers on Oracle Fusion HCM cloud software. See our latest analysis for Oracle. At a share price of US$143.47, Oracle has seen a strong 7 day share price return of 12.47%, although the 90 day share price return is down 26.78% and the 1 year total shareholder return is down 41.82%. This indicates that recent momentum follows a...

Aeva Technologies, Inc. reported past second-quarter 2026 results with revenue of US$6.14 million and a net loss of US$79.62 million, while also announcing its CFO will depart in September 2026. At the same time, Aeva launched an Optical Connectivity business and entered a joint development agreement to bring its high-power photonics to AI data centers, potentially broadening its commercial reach beyond automotive sensing. Next, we’ll examine how Aeva’s new Optical Connectivity venture for...

In the second quarter of 2026, Valero Energy Corporation reported that sales rose to US$42,816 million and net income to US$3,720 million compared with the prior year, and it completed a share repurchase program totaling 48,114,319 shares, or 15.33% of its share count, for US$8.42 billion under its 2023 authorization. This combination of sharply higher earnings per share and extensive buybacks, alongside recent upgrades in earnings estimates, has reinforced analysts’ positive view of...

Enact Holdings (ACT) has drawn fresh investor attention after reporting second quarter 2026 results, updating its capital return plans, and outlining operational changes that include a new AI driven underwriting tool. See our latest analysis for Enact Holdings. The recent Q2 2026 earnings beat, higher capital return guidance, dividend affirmation, and progress on the AI underwriting tool appear to sit behind Enact Holdings’ 22.84% year to date share price return and 85.69% three year total...

Salesforce stock has fallen 26.4% year to date, yet on the current checks it still screens as relatively cheap compared with its fundamentals. This sets up a clear question about whether the recent share price is fully reflecting the business outlook. Year to date the share price is down 26.4%, which puts Salesforce on the back foot even after recent short term gains. Large public sector AI deals and expanding use of its Agentforce and Missionforce platforms can support growth expectations,...

Arista Networks (ANET) just reported record second quarter results, with revenue topping US$3.0b and both earnings and sales ahead of expectations. Management also raised its full year and third quarter outlook. See our latest analysis for Arista Networks. At a share price of US$192.32, Arista Networks has pulled back slightly in the last day but still sits on a strong 7 day share price return of about 12% and a year to date share price return of roughly 44%, alongside a very large 5 year...

IREN (NasdaqGS:IREN) has drawn attention after securing US$2.8b in multi-year AI cloud contracts with Microsoft and Nvidia, lifting its year-end AI cloud run-rate target and closing the Mirantis acquisition. See our latest analysis for IREN. Despite the AI cloud contracts and Mirantis deal, IREN’s share price has cooled in recent months, with a 30 day share price return of 4.7% lower and a 90 day share price return of 38% lower. Even so, the 1 year total shareholder return of 104.25% and very...

HP stock has gained 27.4% year to date, and both its intrinsic value estimate using a Discounted Cash Flow (DCF) approach and its market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. Year to date, HP is up 27.4%, which puts the recent share price strength against a backdrop of valuation indicators that still suggest upside relative to intrinsic value. Momentum around HP's AI focused PC shipments can support expectations for...

Amylyx Pharmaceuticals (AMLX) shares moved after the company reported second quarter 2026 results, which showed a net loss of US$43.42 million and basic loss per share from continuing operations of US$0.39. See our latest analysis for Amylyx Pharmaceuticals. The latest earnings update appears to have sharpened attention on Amylyx Pharmaceuticals, with the share price at US$24.19 and a 1-day share price return of 10.71%, building on a 30-day share price return of 33.13% and a 1-year total...

Peoples Bancorp stock performance snapshot Peoples Bancorp (PEBO) has drawn investor interest after a recent share price move, trading at $41.16 as of its latest close. The stock has been relatively steady over the past week. Over the past month, Peoples Bancorp has posted a gain of 6.96%, while the past 3 months show a 19.93% return. The stock’s 1 year total return stands at 53.12%. See our latest analysis for Peoples Bancorp. For Peoples Bancorp, the recent 1 month share price return of...

Why BigBear.ai Holdings is Back on Investors' Radar BigBear.ai Holdings (BBAI) has drawn fresh attention after reporting second quarter results with higher sales, a sharply smaller net loss, and reaffirmed full year 2026 revenue guidance, giving investors clearer visibility on the current outlook. See our latest analysis for BigBear.ai Holdings. The recent earnings update and reaffirmed 2026 revenue guidance have come after a tough stretch for BigBear.ai Holdings, with the share price down...